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Abstract 
A generally applicable synthesis has been developed for 2-substituted oxirane-2-carboxylic 
esters, which have attracted interest as inhibitors of carnitine palmitoyltransferase-1 (CPT-1) for 
the treatment of non-insulin-dependent diabetes mellitus (NIDDM). The route involves 
alkylation of the dianion of 2-methyl-2-propen-1-ol (methallyl alcohol) followed by Sharpless 
epoxidation. The utility of the method has been demonstrated by the synthesis of (R)-Etomoxir, 
the best known member of this class of compounds, and ethyl (R)-2-[6-(2,4-
dinitrophenoxy)hexyl]oxirane-carboxylate, previously synthesised only as a racemate. The high 
enantiomeric purity of the compounds has been demonstrated by formation of Mosher esters of 
the products of Sharpless epoxidation and analysis by 1H NMR spectroscopy. 
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Introduction 
 
The enzyme carnitine palmitoyltransferase-1 (CPT-1) catalyses the conversion of long-chain 
fatty-acid CoA esters, principally the CoA ester 1 of palmitic acid, to carnitine esters such as 2. 
The latter can enter the mitochondria, where they are converted back to CoA esters by another 
carnitine palmitoyltransferase, CPT-2 (Figure 1).1 
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Figure 1. Interconversion of CoA and carnitine esters. 
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Inside the mitochondria, CoA esters are metabolised by iterative β-oxidations to acetyl CoA, 
which enters the citric acid cycle, ultimately being degraded to CO2 with the production of ATP. 
By blocking entry of fatty-acid CoA esters into the mitochondria, production of acetyl CoA, 
ATP and NADH are reduced, thus attenuating gluconeogenesis and hepatic glucose production.2 
Further, the body is forced to rely on glycolysis for the production of acetyl CoA.3 Therefore, 
CPT-1 inhibitors have hypoglycaemic (blood-sugar-lowering) effects and have attracted 
attention as potential treatments for type-2, or non-insulin-dependent diabetes mellitus 
(NIDDM).4 
One class of CPT inhibitors is the substituted oxirane carboxylates, of which the best known 
is probably Etomoxir 3a (Figure 2).5 These compounds, of which only the (R) enantiomer is 
active, are converted to CoA esters in the body, mimicking fatty-acid CoA esters. They bind to 
CPT-1, whereupon the enzyme is covalently alkylated by the epoxide, probably at a histidine 
residue.6 Hence, these compounds are irreversible inhibitors. Etomoxir was never brought to 
market however, due to the very  large doses needed for efficacy,7 as well as side-effects such as 
cardiac hypertrophy.8 These side effects are due in part to the lack of selectivity (of Etomoxir 3a 
and other similar compounds) for the liver isoform of CPT-1 (L-CPT-1) over the skeletal muscle 
isoform (M-CPT-1). 
M-CPT-1 is the major isoform in the heart, and unwanted inhibition of this isoform is a 
major factor in the side-effects. To overcome this, the L-CPT-1-selective inhibitor ethyl 2-[6-
(2,4-dinitro-phenoxy)-hexyl]oxiranecarboxylic 4 (Figure 2) was developed, although only as a 
racemate.9,10 (The free acid form, prepared via a silyl ester rather than the ethyl ester, was used 
for biological testing). 
 
O
OEt
O
O
Cl Etomoxir 3a
R
O
OEt
O
O
NO2O2N 4  
 
Figure 2. 2-Substituted oxirane-2-carboxylates as CPT-1 inhibitors. 
 
Although Etomoxir 3a has not been accepted for use treating NIDDM, it has more recently 
shown potential as a treatment for chronic heart failure.11 Combined with the demonstration with 
compound 4 that the side-effects of substituted oxirane-2-carboxylates can be overcome, it seems 
likely that these compounds and analogues will continue to attract attention. Hence, we have 
developed a new synthetic methodology for substituted oxirane-2-carboxylates, exemplified by 
syntheses of 3a and monochiral 4 [(R)-enantiomer 4a]. 
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Results and Discussion 
 
The key transformations in our method are (i) alkylation of the dianion of methallyl alcohol (2-
methyl-2-propen-1-ol) with a bromide corresponding to the desired side-chain of the target, (ii) 
Sharpless epoxidation12 of the resulting allyl alcohol, and (iii) oxidation and esterification of the 
Sharpless product. Various other published syntheses introduce the chirality by enzymatic 
resolution13,14 and via a chiral auxiliary.15 Sharpless epoxidation has been reported before in the 
synthesis of Etomoxir 3a, but the synthesis of the necessary precursor 7 was long and 
inconvenient.16 Our synthesis of precursor 7 is just two steps, and the complete synthesis of 
Etomoxir 3a just four steps. (Scheme 1.) 
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Scheme 1. Reagents and conditions: i, Br-(CH2)5-Br, NaOH, Bu4N.HSO4, H2O, 100 °C, 18 h; ii, 
Methallyl alcohol, n-BuLi, TMEDA, diethyl ether, petrol, -78 → 25 °C, N2, 16 h, then add 6,      
-78→ 25 °C, N2, 1 h; iii, L-(+)-diethyl tartrate, Ti(OiPr)4, t-BuOOH, powdered 4Å molecular 
sieves, CH2Cl2, -5 → -20 °C, N2, 3 h; iv, RuCl3, NaIO4, H2O, CH3CN, CCl4, 25 °C, 6 h then EtI, 
KHCO3, DMF, 25 °C, overnight. 
 
4-Chlorophenol 5 was alkylated with an excess of 1,5-dibromopentane, sodium hydroxide 
and a phase-transfer catalyst to give the bromide 6 in a slightly modified literature procedure.17 
This was used to alkylate methallyl alcohol, doubly deprotonated with butyl lithium in the 
presence of TMEDA. We found that this reaction can be facilitated by using 2.5 M butyl lithium 
diluted to 1.6 M with diethyl ether, and also by allowing the reaction mixture to warm from -78 
°C to room temperature over one hour after addition of the bromide. The resulting allyl alcohol 7 
was epoxidised under modified Sharpless conditions using L-(+)-diethyl tartrate as the ligand to 
give compound 8a, or using D-(-)-diethyl tartrate to give the (R)-enantiomer 8b (not pictured). 
These stereochemical outcomes are based on the accepted model.18 Alternatively, epoxidation 
with mCPBA gave the corresponding racemate (compound 8c, not pictured). The final step in the 
synthesis was ruthenium-catalysed periodate oxidation of 8a and esterification of the resulting 
crude acid. We initially used diethyl sulfate but found that ethyl iodide was superior, being less 
toxic and easier to remove. The product (R)-Etomoxir 3a (or (S)-Etomoxir 3b, not pictured, from 
(R) epoxy alcohol 8b) was easily purified by chromatography on silica. Finally, (R)-Etomoxir 3a 
Issue in Honor of Prof. Rod Rickards ARKIVOC 2004 (x) 118-133 
ISSN 1424-6376 Page 121 ©ARKAT USA, Inc 
could if desired be hydrolysed using sodium hydroxide to give (R)-Etomoxir, sodium salt 10a 
(not pictured), and likewise (S)-Etomoxir 3b gave (S)-Etomoxir sodium salt 10b (not pictured). 
The high enantiomeric purity of the Etomoxir 3a was proved by formation of an ester 9a of 
its precursor epoxy alcohol 8a with (R)-α-methoxy-α-trifluoromethylphenylacetic acid (Mosher’s 
acid),19 using diisopropylcarbodiimide as the coupling reagent and DMAP as catalyst (Scheme 
2). 
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Scheme 2. Reagents and conditions: i, (R)-Mosher’s acid, diisopropyl-carbodiimide, DMAP, 
DMF, 0 °C, N2, 18 h. 
 
Both 8a and its enantiomer 8b were converted to (R)-Mosher esters for comparison 
(compounds 9a and 9b respectively). The crude samples were analysed by 1H NMR before 
purification, and the peaks of the AB system corresponding to the diastereotopic CH2 group 
indicated in Figure 3 were carefully integrated. In both cases, a diastereoisomeric ratio of 98 : 2, 
corresponding to an e.e. of at least 96 % for 8a and 8b, was observed. The 1H NMR spectra for 
these CH2 groups are shown in Figure 3. 
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Figure 3. 1H NMR of the diastereotopic CH2 groups of 9a and 9b. 
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The synthesis of ethyl (R)-2-[6-(2,4-dinitrophenoxy)-hexyl]-oxiranecarboxylate 4a required a 
partly different strategy. We began by attempting an exactly analogous synthesis to that 
described for (R)-Etomoxir, and accordingly alkylated 2,4-dinitrophenol 11 with an excess of 
1,5-dibromopentane in the presence of sodium hydroxide and a phase-transfer catalyst to give the 
bromide 12 in good yield (Scheme 3). Unfortunately, trying to use 12 to alkylate doubly 
deprotonated methallyl alcohol resulted only in the formation of a black tar containing none of 
the desired product 13. 
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Scheme 3. Reagents and conditions: i, Br-(CH2)5-Br, NaOH, Bu4N.HSO4, H2O, 100 °C, 18 h. 
 
It was decided to defer coupling of the dinitrophenoxy group until after the methallyl alcohol 
alkylation, substituting the triisopropylsilyl (TIPS) group as a protecting group in the meantime 
(Scheme 4). [Mass spectra of compounds containing the TIPS group always gave signals 
showing fragmentative loss of one isopropyl group (C3H7, mass = 43) and no M+ ion]. 
 
i, 85% TIPSO BrHO Br
O
OEt
O
TIPSO
OH
O
TIPSO S
R
TIPSO
OH
O
OEt
O
HO R
O
OEt
O
O
NO2O2N
R
14 15
16 17a
19
20  4a
ii, 66 %
iii, 65 %
iv, 48 % v, 74 %
vi, 58 % 
or
vii, 61 %
 
 
Scheme 4. Reagents and conditions: i, TIPS-Cl, imidazole, DMF, 25 °C, 3 h; ii, Methallyl 
alcohol, n-BuLi, TMEDA, diethyl ether, petrol, -78 → 25 °C, N2, 16 h, then add 15, -78 → 
25 °C, N2, 1 h; iii, L-(+)-diethyl tartrate, Ti(OiPr)4, t-BuOOH, powdered 4Å molecular sieves, 
CH2Cl2, -5 → -20 °C, N2, 3 h; iv, RuCl3, NaIO4, H2O, CH3CN, CCl4, 25 °C, 6h then EtI, 
KHCO3, DMF, 25 °C, overnight; v, TBAF, THF, 25 °C, 1 h; vi, 2,4-dinitrofluorobenzene, 
DABCO, DMF, 25 °C, 48 h; vii, 2,4-dinitrophenol, DEAD, PPh3, THF, 0 → 25 °C, 18 h. 
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5-Bromo-1-pentanol 14 was prepared according to a literature procedure,20 and protected 
using triisopropylsilyl chloride and imidazole in DMF to give bromide 15. This underwent 
coupling with deprotonated methallyl alcohol satisfactorily in the presence of TMEDA to give 
allyl alcohol 16. This was epoxidised under modified Sharpless conditions using L-(+)-diethyl 
tartrate as the ligand to give compound 17a, D-(-)-diethyl tartrate to give the (R) enantiomer 17b 
(not pictured), or mCPBA to give racemate 17c (not pictured). Enantiomeric purity (e.e. ≥96 %) 
was again proved by the formation of (R)-Mosher esters as above (not pictured, compounds 18a 
and 18b for the (S) and (R) enantiomers respectively in the experimental section).  
Epoxy alcohol 17a was oxidised and esterified under the same conditions which yielded 
Etomoxir 3a to give ester 19, and the protecting group was removed using tetrabutylammonium 
fluoride (TBAF) in THF to give alcohol 20. This alcohol should be used promptly as it appears 
to go off on standing. 
The final step was the coupling of 20 with a source of the 2,4-dinitrophenoxy group to yield 
the target compound 4a. To achieve this, two approaches were examined: nucleophilic aromatic 
substitution with 2,4-dinitrofluorobenzene, and Mitsunobu reaction21 with 2,4-dinitrophenol. The 
Mitsunobu reaction, which has been used in the synthesis of 2-substituted-oxirane-2-
carboxylates previously,15,22 was the better of the two, 2,4-dinitrofluorobenzene giving difficult-
to-reproduce results and sometimes yielding compound 4a contaminated with an unidentified 
impurity difficult to remove by chromatography. 
Overall, this route is slightly longer than the route which yielded Etomoxir 3a, but has the 
advantage that the use of the Mitsunobu reaction allows for the dereferal of the coupling of the 
aromatic group until after the formation of the oxirane-carboxylate portion of the molecule. This 
opens up the possibility of the synthesis of a wide variety of chemically sensitive or non-
phenolic analogues. 
 
 
Conclusions 
 
In conclusion, we have developed a versatile and efficient route to 2-substituted oxirane-2-
carboxylates, which should allow the synthesis of a broad range of analogues in enantiomerically 
pure form. In doing so, we have developed the shortest synthesis yet published of Etomoxir. 
 
 
Experimental Section 
 
General Procedures. Anhydrous solvents were purchased from Fluka, and n-butyllithium from 
Sigma-Aldrich. TMEDA and methallyl alcohol were distilled immediately before use. tert-Butyl 
hydrogen peroxide in anhydrous toluene was prepared according to the method of Sharpless.23 
All other reagents were used as received. Column chromatography on silica refers to medium 
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pressure chromatography using Davisil 40 - 63µ silica gel, Fluorochem, Derbyshire, UK. Optical 
rotations were recorded at 589 nm. 
1-Bromo-5-(4-chlorophenoxy)-pentane (6). To NaOH (4.6 g, 115 mmol) in water (120 mL) 
was added 4-chlorophenol (6.48 g, 50.9 mmol) portionwise with stirring. Tetrabutylammonium 
hydrogensulfate (116 mg, 0.34 mmol) was added followed by 1,5-dibromopentane (28 mL, 
47.5 g, 197 mmol), and the mixture was heated at reflux overnight. The mixture was allowed to 
cool and extracted with diethyl ether (3 × 100 mL). The combined organic extracts were dried 
(MgSO4) and concentrated to an oil which was heated in vacuo (10 mmHg, 140 °C) to remove 
excess 1,5-dibromopentane. The residual oil was purified by column chromatography on silica 
(eluting with diethyl ether-petrol, 5 : 95) to yield the title compound as a colourless oil, 12.56 g 
(89%); Rf 0.77 (ethyl acetate-petrol, 1 : 4); νmax/cm-1 2942, 2867, 1492, 1472, 1286, 1244, 824; 
δH (300 MHz, CDCl3) 7.15 (d, J = 8.7 Hz, 2H, 2 × ArH), 6.74 (d, J = 8.8 Hz, 2H, 2 × ArH), 3.87 
(t, J = 6.3 Hz, 2H, CH2OAr), 3.37 (t, J = 6.7 Hz, 2H, CH2Br), 1.84 (quintet, J = 7.5 Hz, 2H, 
CH2), 1.73 (quintet, J = 6.9 Hz, 2H, CH2), 1.56 (quintet, J = 6.9 Hz, 2H, CH2); δC (75.45 MHz, 
CDCl3) 157.7, 129.4, 125.6, 115.8, 68.0, 33.6, 32.5, 28.5, 24.9; m/z 280 (M+, 7%), 278 (25%), 
276 (21), 151 (19), 149 (16), 130 (17), 128 (54), 69 (100); HRMS: calcd for C11H1479Br 35ClO 
275.9917, found 275.9903. 
8-(4-Chlorophenoxy)-2-methylene-octan-1-ol (7). To anhydrous diethyl ether (15 mL) was 
added n-butyllithium (44 mL of a 2.5 M solution in hexane, 110 mmol) under N2, and the 
resulting solution was cooled to –78 °C. Freshly distilled tetramethylethylenediamine (16.7 mL, 
12.9 g, 111 mmol) was added dropwise and the mixture was allowed to stand for 10 min. 
Methallyl alcohol (4.6 mL, 4.0 g, 55 mmol) was added dropwise, and the mixture was stirred 
overnight and allowed to warm to room temperature. After recooling to –78 °C, 1-bromo-5-(4-
chlorophenoxy)-pentane 6 (6.39 g, 23.0 mmol) in THF (15 mL) was added dropwise. The 
mixture was stirred for 1 h, warming to room temperature. Aqueous HCl (0.5 M, 50 mL) was 
added cautiously. The mixture was partitioned between water and diethyl ether, the layers 
separated and the aqueous layer re-extracted with diethyl ether (3 × 50 mL). The combined 
organic layers were dried (MgSO4) and concentrated to a residue which was purified by column 
chromatography on silica (eluting with ethyl acetate-petrol, 10 : 90). The title compound was 
obtained as a colourless oil, 4.46 g (72%); Rf 0.60 (ethyl acetate-petrol, 2 : 3); νmax/cm-1 3343 
(br), 2933, 2858, 1492, 1245, 824; δH (300 MHz, CDCl3) 7.14 (d, J = 8.9 Hz, 2H, 2 × ArH), 6.73 
(d, J = 8.9 Hz, 2H, 2 × ArH), 4.95 (s, 1H, =CH), 4.80 (s, 1H, =CH), 4.01 (s, 2H, CH2OH), 3.84 
(t, J = 6.5 Hz, 2H, CH2OAr), 2.01 (t, J = 7.3 Hz, 2H, CH2C=C), 1.70 (quintet, J = 6.9 Hz, 2H, 
CH2), 1.50 – 1.25 (m, 6H, 3 × CH2); δC (75.45 MHz, CDCl3) 157.8, 149.1, 129.3, 125.4, 115.8, 
109.3, 68.3, 66.0, 32.9, 29.2, 27.6, 25.9; m/z 270 (M+, 30%), 268 (100), 130 (26), 128 (93), 81 
(95); HRMS: calcd for C15H2135ClO2 268.1230, found 268.1226. 
(S)-{2-[6-(4-Chloro-phenoxy)-hexyl]-oxiranyl}-methanol (8a). To a slurry of powdered 4Å 
molecular sieves (0.56 g) in anhydrous dichloromethane (15 ml) under N2 at –5 °C were added 
L-(+)-diethyl tartrate (1.2 mL, 1.48 g, 7.17 mmol followed by titanium (IV) isopropoxide 
(1.4 mL, 1.35 g, 4.75 mmol). The mixture was cooled to –20 °C and tert-butyl hydroperoxide 
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(4.0 mL of a 3.6 M solution in anhydrous toluene, 14.5 mmol) was added. The mixture was 
allowed to stand for 10 min, and 8-(4-chloro-phenoxy)-2-methylene-octan-1-ol 7 (2.5 g, 9.31 
mmol) in anhydrous dichloromethane (6 mL) was added dropwise. The mixture was stirred at –
15 °C for 3 h, quenched with water (25 mL), allowed to warm to room temperature and stirred 
for 1 h. A solution of NaCl (0.25 g) and NaOH (0.75 g) in water (2 mL) was added and the 
mixture was stirred overnight, then filtered through Celite, and extracted with dichloromethane 
(2 × 25 mL). The combined dichloromethane layers were dried (MgSO4) and concentrated to a 
residue which was purified by column chromatography on silica (eluting with diethyl ether-
petrol, 30 : 70 →  50 : 50) to yield the title compound as a white solid, 2.11 g (80%); Rf 0.36 
(ethyl acetate-petrol, 2 : 3); mp 44 – 45 °C (from petrol-diethyl ether); [α]D -1.7 (c = 0.01 g mL-1 
in MeOH); νmax/cm-1 3434 (br), 2861, 2937, 1493, 1245, 825; δH (300 MHz, CDCl3) 7.14 (d, J = 
8.9 Hz, 2H, 2 × ArH), 6.73 (d, J = 8.9 Hz, 2H, 2 × ArH), 3.81 (t, J = 6.4 Hz, 2H, CH2OAr), 3.71 
+ 3.57 (AB system, J = 12.2 Hz, 2H, CH2OH), 2.81 + 2.60 (AB system, J = 4.6 Hz, 2H, epoxide 
CH2), 1.69 (t, J = 7.3 Hz, 2H, CH2), 1.6 – 1.5 (m, 4H, 2 × CH2), 1.5 – 1.2 (m, 4H, 2 × CH2); δC 
(75.45 MHz, CDCl3) 157.7, 129.4, 125.4, 115.8, 68.2, 62.9, 59.8, 49.9, 31.9, 29.5, 29.1, 26.0, 
24.6; m/z 286 (M+, 33%), 284 (94), 196 (11), 141 (17), 130 (95), 128 (100); HRMS: calcd for 
C15H2135ClO3 284.1181, found 284.1177. 
(R)-{2-[6-(4-Chloro-phenoxy)-hexyl]-oxiranyl}-methanol (8b). Treatment of 8-(4-Chloro-
phenoxy)-2-methylene-octan-1-ol 7 (2.5 g, 9.3 mmol) as described above but employing D-(-)-
diethyl tartrate yielded the title compound as a white solid, 1.85 g (70%), which showed identical 
analytical data as the (S) enantiomer 8a, except [α]D +1.8 (c = 0.01 g mL-1 in MeOH) 
Rac-{2-[6-(4-Chloro-phenoxy)-hexyl]-oxiranyl}-methanol (8c). To an ice-cold solution of 8-
(4-chlorophenoxy)-2-methylene-octan-1-ol 7 (1.5 g, 5.59 mmol) in dichloromethane (50 mL) 
was added m-chloroperbenzoic acid (c. 90% pure, 1.28 g, 6.7 mmol) in dichloromethane (50 mL) 
dropwise. The mixture was allowed to warm to room temperature and stirred overnight. After 
this period, analysis by TLC (ethyl acetate-petrol, 2 : 3) showed starting material remaining, so 
m-chloro-perbenzoic acid (0.20 g, 1.05 mmol) was added and the solution was heated at 40 °C 
for 1 h. The solution was allowed to cool and washed with aqueous Na2SO3 (2 × 50 mL), 
aqueous NaHCO3 (2 × 50 mL), and water (50 mL), then dried (MgSO4) and concentrated  to 
yield the title compound as a colourless oil, 1.60 g (99%), which gave essentially identical 
analytical data as the (S) enantiomer 8a. Rf 0.36 (ethyl acetate-petrol, 2 : 3); HRMS: calcd for 
C15H2135ClO3 284.1181, found 284.1179. 
(R)-Mosher’s ester of (S)-{2-[6-(4-chlorophenoxy)-hexyl]-oxiranyl}-methanol (9a). To a 
solution of (S)-{2-[6-(4-chlorophenoxy)-hexyl]-oxiranyl}-methanol 8a (150 mg, 0.53 mmol) in 
DMF (5 mL) was added (R)-(+)- α-methoxy-α-trifluoromethylphenylacetic acid (Mosher’s acid, 
500 mg, 2.06 mmol), DMAP (10 mg, 82 µmol) and powdered 4Å molecular sieves (50 mg), and 
the mixture was cooled to 0 °C under N2. Diisopropyl carbodiimide (0.3 mL, 243 mg, 1.93 
mmol) was added dropwise, and the whole was allowed to warm to room temperature and stirred 
overnight. The mixture was poured into water and extracted with diethyl ether (2 × 20 mL). The 
combined organic layers were washed with water (2 × 20 mL), saturated aqueous NaHCO3 (20 
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mL), 2 M HCl (20 mL) and brine (20 mL), then dried (MgSO4), and concentrated to an oil. 1H 
NMR analysis showed that the crude sample was a 98 : 2 mixture of diastereoisomers. 
Purification by column chromatography on silica (eluting with CH2Cl2-petrol, 60 : 40 → 100 : 0) 
yielded the title compound as a colourless oil, 190 mg (74%); Rf 0.35 (diethyl ether-petrol, 3 : 1); 
νmax/cm-1 2942, 2861, 1753, 1492, 1245, 1170, 1026; δH (300 MHz, CDCl3) 7.50 (m, 2H, 2 × 
ArH), 7.40 (m, 3H, 3 × ArH), 7.15 (d, J = 8.9 Hz, 2H, 2 × ArH), 6.74 (d, J = 8.9 Hz, 2H, 2 × 
ArH), 4.48 + 4.11 (AB system, J = 11.9 Hz, 2H, CH2O.C=O), 3.83 (t, J = 6.4 Hz, 2H, CH2OAr), 
3.48 (s, 3H, CH3O), 2.63 + 2.59 (AB system, J = 4.5 Hz, 2H, epoxide CH2), 1.7 -1.6 (m, 2H, 
CH2), 1.6 – 1.5 (m, 2H, CH2), 1.4 – 1.1 (m, 6H, 3 × CH2), δC (75.45 MHz, CDCl3) 167.5, 158.1, 
130.1, 129.7, 129.2, 128.9, 127.7, 127.2, 116.1, 68.5, 67.8, 57.1, 50.9, 48.9, 43.4, 31.9, 29.6, 
29.4, 26.2, 24.7, 22.3; m/z 502 (M+, 12%), 500 (35), 203 (7), 189 (100), 128 (50); HRMS: calcd 
for C25H2835ClF3O5 500.1597, found 500.1577. 
(R)-Mosher’s ester of (R)-{2-[6-(4-chlorophenoxy)-hexyl]-oxiranyl}-methanol (9b). (R)-{2-
[6-(4-chlorophenoxy)-hexyl]-oxiranyl}-methanol 8b (150 mg, 0.53 mmol) was treated with (R)-
Mosher’s acid as above. 1H NMR analysis showed that the crude sample was a 98 : 2 mixture of 
diasteroisomers. Column chromatography on silica (eluting with CH2Cl2-petrol, 60 : 40 → 100 : 
0) yielded the title compound as a colourless oil, 154 mg (60%); Rf 0.35 (diethyl ether-petrol, 3 : 
1); νmax/cm-1 2942, 2861, 1753, 1492, 1245, 1170, 1026; δH (300 MHz, CDCl3) 7.50 (m, 2H, 2 × 
ArH), 7.40 (m, 3H, 3 × ArH), 7.15 (d, J = 8.9 Hz, 2H, 2 x ArH), 6.74 (d, J = 8.9 Hz, 2H, 2 × 
ArH), 4.42 + 4.21 (AB system, J = 12.0 Hz, 2H, CH2O.C=O), 3.83 (t, J = 6.4 Hz, 2H, CH2OAr), 
3.48 (s, 3H, CH3O), 2.67 + 2.59 (AB system, J = 4.8 Hz, 2H, epoxide CH2), 1.7 -1.6 (m, 2H, 
CH2), 1.6 – 1.5 (m, 2H, CH2), 1.4 – 1.1 (m, 6H, 3 × CH2), δC (75.45 MHz, CDCl3) 167.7, 157.9, 
130.1, 129.7, 129.2, 128.9, 127.2, 125.6, 116.1, 68.5, 67.1, 57.1, 50.7, 48.9, 43.4, 32.2, 29.7, 
29.4, 26.2, 24.7, 22.4; m/z 502 (M+, 20%), 500 (56), 203 (7), 189 (100), 128 (41); HRMS: calcd 
for C25H2835ClF3O5 500.1597, found 500.1585. 
(R)-Etomoxir (3a). To a vigorously stirred solution of (S)-{2-[6-(4-chlorophenoxy)-hexyl]-
oxiranyl}-methanol 8a (1.6 g, 5.62 mmol) in tetrachloromethane (11 mL) and acetonitrile (11 
mL) at room temperature was added sodium periodate (3.59 g, 16.87 mmol) in water (17 mL) 
followed by ruthenium trichloride trihydrate (32 mg, 0.12 mmol). After 6 h, the mixture was 
extracted with dichloromethane (2 × 40 mL), and the combined organic extracts were washed 
with brine (20 mL), dried (MgSO4) and concentrated to a black residue. This was dissolved in 
anhydrous DMF (12 mL) and treated with ethyl iodide (0.80 mL, 1.56 g, 10.0 mmol) followed 
by portionwise addition of KHCO3 (0.68 g, 6.7 mmol). The mixture was stirred overnight, 
poured into water and extracted with hexane (3 × 40 mL). The combined hexane layers were 
dried (MgSO4) and concentrated to a residue which was purified by column chromatography on 
silica (eluting with diethyl ether-petrol, 20 : 80) to yield the product as a colourless oil, 0.98 g 
(53%); Rf 0.36 (diethyl ether-petrol, 1 : 3); νmax/cm-1 2938, 2863, 1734, 1493, 1399, 1388, 1245, 
1196, 1005, 922, 827; δH (300 MHz, CDCl3) 7.23 (d, J = 8.9 Hz, 2H, 2 × ArH), 6.83 (d, J = 8.9 
Hz, 2H, 2 × ArH), 4.26 (m, 2H, CH2CH3), 3.93 (t, J = 6.5 Hz, 2H, CH2OAr), 3.05 + 2.79 (AB 
system, J = 5.9 Hz, 2H, epoxide CH2), 1.8 -1.7 (m, 2H, CH2), 1.7 – 1.6 (m, 2H, CH2), 1.5 – 1.40 
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(m, 6H, 3 × CH2), 1.31 (t, J = 7.1 Hz, 3H, CH3); δC (75.45 MHz, CDCl3) 170.4, 157.7, 129.2, 
125.3, 115.7, 68.1, 61.6, 57.0, 51.8, 31.1, 29.2, 29.0, 25.8, 24.7, 14.6; m/z 328 (M+, 15%), 326 
(46), 153 (6), 141 (10), 130 (32), 128 (100), 107 (20); HRMS: calcd for C17H2335ClO4 326.1285, 
found 326.1283. 
(S)-Etomoxir (3b). Treatment of (R)-{2-[6-(4-Chloro-phenoxy)-hexyl]-oxiranyl}-methanol 8b 
(0.70 g, 2.45 mmol) as described above yielded the title compound as a colourless oil,  0.50 g 
(63%), which showed identical analytical data as the (R) enantiomer 3a. 
(R)-Etomoxir, sodium salt (10a). (R)-Etomoxir 3a (0.77 g, 2.36 mmol) was dissolved in THF 
and treated with 1.036 M volumetric standard aqueous NaOH solution (2.27 mL, 2.35 mmol) 
dropwise. The mixture was stirred overnight, then concentrated to a slurry of white crystals, 
which were dissolved in the minimum volume of boiling acetone, cooled and treated with diethyl 
ether dropwise to induce crystallization. After storage overnight in a freezer, the crystals were 
collected by suction filtration, washed with ether and dried under vacuum (0.05 mmHg, 40 °C) 
to afford the product as a dihydrate, 0.37 g (44%); (Found: C, 50.65; H, 6.1. Calc. for 
C15H18O4NaCl.2H2O: C, 50.5; H, 6.2 %); [α]D +17.6 (c = 0.01 g mL-1 in MeOH)†; νmax/cm-1 3404 
(br), 2930, 1600, 1493, 1244, 820; δH (300 MHz, DMSO-d6) 7.34 (d, J = 9.0 Hz, 2H, 2 × ArH), 
6.98 (d, J = 9.0 Hz, 2H, 2 × ArH), 3.97 (t, J = 6.6 Hz, 2H, CH2OAr), 3.40 (s, 4H, water), 2.68 + 
2.48 (AB system, J = 6.4 Hz, 2H, epoxide CH2), 2.00 – 1.90 (m, 1H, 0.5 × CH2), 1.72 (quintet, J 
= 7.0 Hz, 2H, CH2) 1.50 – 1.30 (m, 7H, 3.5 × CH2); δC (75.45 MHz, DMSO-d6) 172.0, 157.5, 
129.2, 123.9, 116.2, 67.8, 58.9, 50.5, 32.9, 29.1, 28.5, 25.5, 25.2. 
(S)-Etomoxir, sodium salt (10b). Treatment of (S)-Etomoxir 3b (0.50 g, 1.53 mmol) as 
described above yielded the title compound as white crystals, 0.33 g (55%) which showed 
identical analytical data as the (R) enantiomer 3a, except [α]D -16.4 (c = 0.01 g mL-1 in MeOH).† 
1-Bromo-5-(2,4-dinitrophenoxy)-pentane (12). To NaOH (0.40 g, 10.0 mmol) in water (10 
mL) was added 2,4-dinitrophenol (0.81 g, 4.4 mmol) portionwise with stirring. 
Tetrabutylammonium hydrogensulfate (10 mg, 2.9 µmol) was added followed by 1,5-
dibromopentane (2.4 mL, 4.1 g, 17.0 mmol), and the mixture was heated at reflux overnight. The 
mixture was allowed to cool and partitioned between water and diethyl ether. The layers were 
separated and the aqueous layer was re-extracted with diethyl ether (3 × 20 mL). The combined 
organic extracts were dried (MgSO4) and concentrated to an oil which was purified by column 
chromatography on silica (eluting with ethyl acetate-petrol, 10 : 90 → 30 : 70). The title 
compound was obtained as a pale yellow solid, 1.21 g (83%); Rf 0.55 (ethyl acetate-petrol, 1 : 3); 
(Found: C, 39.7; H, 3.8; N, 8.35. Calc. for C11H13BrN2O5: C, 39.65; H, 3.9; N, 8.4 %); νmax/cm-1 
2947, 1608, 1521, 1343, 1280; δH (300 MHz, CDCl3) 8.69 (d, J = 2.8 Hz, 1H, ArH), 8.36 (dd, J 
= 2.8, 9.3 Hz, 1H, ArH), 7.13 (d, J = 9.3 Hz, 1H, ArH), 4.18 (d, J = 6.2 Hz, 2H, CH2OAr), 3.39 
(t, J = 6.6 Hz, 2H, CH2Br), 1.94 – 1.82 (m, 4H, 2 × CH2), 1.67 – 1.57 (m, 2H, CH2); δC (75.45 
MHz, CDCl3) 157.1, 140.4, 139.3, 129.4, 125.6, 122.3, 114.5, 70.7, 33.6, 32.5, 28.3, 24.9; m/z 
334 (M+, 15%), 332 (17), 151 (65), 149 (61), 41 (100); HRMS: calcd for C11H1379BrN2O5 
332.0003, found 332.0008. 
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1-Bromo-5-(triisopropyl-silyloxy)-pentane (15). To a solution of 1-bromopentan-5-ol 14 
(9.38 g, 56.0 mmol) in anhydrous DMF (200 mL) under N2 at 5 °C was added imidazole (8.04 g, 
120.0 mmol) followed by triisopropylsilyl chloride (12.8 mL, 11.55 g, 60.0 mmol) dropwise over 
30 min. The mixture was stirred 3 h, then poured into water and extracted with diethyl ether (2 × 
100 mL). The combined organic layers were washed with 1 M HCl (50 mL) and water (5 × 50 
mL), swirled with solid NaHCO3, dried (MgSO4) and concentrated to an oil. Column 
chromatography on silica (eluting with diethyl ether-petrol, 2 : 98 → 5 : 95) yielded the product 
as a colourless oil, 15.4 g (85%); Rf 0.40 (petrol); νmax/cm-1 2942, 2865, 1463, 1109, 882; δH (300 
MHz, CDCl3) 3.62 (t, J = 6.1 Hz, 2H, CH2OSi), 3.35 (t, J = 6.9 Hz, 2H, CH2Br), 1.82 (quintet, J 
= 7.0 Hz, 2H, CH2), 1.52 – 1.41 (m, 4H, 2 × CH2), 1.00 – 0.97 (m, 21H, 3 × iPr); δC (75.45 MHz, 
CDCl3) 63.5, 34.3, 33.1, 32.5, 25.0, 18.4, 12.4; m/z  281 (M+ – C3H7, 29%), 279 (29), 195 (25), 
197 (25), 183 (98), 181 (100), 167 (35), 165 (36); HRMS: calcd for C11H2479BrOSi (i.e. M+ – 
C3H7) 279.0768, found 279.0779. 
8-(Triisopropyl-silyloxy)-2-methylene-octan-1-ol (16). To anhydrous diethyl ether (20 mL) 
was added n-butyllithium (40 mL of a 2.5 M solution in hexane, 100 mmol) under N2, and the 
resulting solution was cooled to –78 °C. Freshly distilled tetramethylethylenediamine (15.0 mL, 
11.5 g, 100 mmol) was added dropwise and the mixture was allowed to stand for 10 min. 
Methallyl alcohol (4.18 mL, 3.58 g, 49.7 mmol) was added dropwise, and the mixture was stirred 
overnight and allowed to warm to room temperature. After recooling to –78 °C, 1-bromo-5-
(triisopropyl-silyloxy)-pentane 15 (10.0 g, 31.0 mmol) in THF (15 mL) was added dropwise. The 
mixture was stirred for 1 h with warming to room temperature, and aqueous HCl (0.5 M, 50 mL) 
was added cautiously. The mixture was partitioned between water and diethyl ether, and the 
aqueous layer was re-extracted with diethyl ether (3 × 50 mL). The combined organic layers 
were dried (MgSO4), and concentrated to a residue which was purified by column 
chromatography on silica (eluting with ethyl acetate-petrol, 5 : 95 → 10 : 90). The title 
compound was obtained as a colourless oil, 6.40 g (66%); Rf 0.57 (ethyl acetate-petrol, 1 : 4); 
νmax/cm-1 2939, 2865, 1464, 1109, 883; δH (300 MHz, CDCl3) 4.94 (s, 1H, =CH), 4.80 (s, 1H, 
=CH), 4.01 (s, 2H, CH2OH), 3.60 (t, J = 6.5 Hz, 2H, CH2OSi), 1.99 (t, J = 7.5 Hz, 2H, 
CH2.C=C), 1.5 – 1.3 (m, 4H, 2 × CH2), 1.3 - 1.2 (m, 4H, 2 × CH2), 0.99 – 0.97 (m, 21H, 3 × iPr); 
δC (75.45 MHz, CDCl3) 149.6, 109.3, 66.3, 63.8, 33.3, 33.3, 29.6, 28.1, 26.1, 18.4, 12.4; m/z 271  
(M+ – C3H7, 29%), 131 (96), 123 (85), 119 (100); HRMS: calcd for C15H31O2Si (i.e. M+ – C3H7) 
271.2093, found 271.2091. 
(S)-{2-[6-(Triisopropyl-silyloxy)-hexyl]-oxiranyl}-methanol (17a). To a slurry of powdered 
4Å molecular sieves (1.0 g) in anhydrous dichloromethane (30 ml) under N2 at –5 °C were added 
L-(+)-diethyl tartrate (2.6 mL, 3.21 g, 15.4 mmol) followed by titanium (IV) isopropoxide (3.0 
mL, 2.90 g, 10.2 mmol). The mixture was cooled to –20 °C and tert-butyl hydroperoxide (8.6 
mL of a 3.6 M solution in anhydrous toluene, 30.0 mmol) was added. The mixture was allowed 
to stand for 10 min, and 8-(triisopropyl-silyloxy)-2-methylene-octan-1-ol 16 (6.28 g, 20.0 mmol) 
in anhydrous dichloromethane (15 mL) was added dropwise. The mixture was stirred at  –15 °C 
for 3 h, quenched with water (40 mL), allowed to warm to room temperature and stirred for 1 h. 
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A solution of NaCl (0.50 g) and NaOH (1.50 g) in water (5 mL) was added and the mixture was 
stirred overnight. 
The mixture was filtered through Celite, extracted with dichloromethane (2 × 50 mL) and ethyl 
acetate (2 × 50 mL) and the combined organic layers dried (MgSO4) and concentrated to a 
residue. Purification by column chromatography on silica (eluting with diethyl ether-petrol, 30 : 
70 → 50 : 50) yielded the title compound as a colourless oil, 4.28 g (65%); Rf 0.43 (ethyl acetate-
petrol, 1 : 4); νmax/cm-1 2940, 2866, 1463, 1105; δH (300 MHz, CDCl3) 3.71 + 3.60 (AB system, J 
= 12.2 Hz, 2H, CH2OH), 3.59 (t, J = 6.5 Hz, 2H, CH2OSi), 2.82 + 2.60 (AB system, J = 4.6 Hz, 
2H, epoxide CH2), 1.5 – 1.4 (m,  4H, 2 × CH2), 1.3 – 1.2 (m, 6H, 3 × CH2), 1.00 – 0.98 (m, 21H, 
3 × iPr);  δC (75.45 MHz, CDCl3) 63.7, 63.1, 60.1, 50.2, 33.3, 32.4, 30.0, 26.1, 25.0, 18.4, 12.4; 
m/z 287 (M+ – C3H7, 18%), 269 (20), 257 (10), 131 (100); HRMS: calcd for C15H31O3Si (i.e. M+ 
– C3H7) 287.2042, found 287.2044. 
(R)-{2-[6-(Triisopropyl-silyloxy)-hexyl]-oxiranyl}-methanol (17b). Treatment of 8-
(triisopropyl-silyloxy)-2-methylene-octan-1-ol 16 (1.0 g, 3.18 mmol) as described above but 
employing D-(-)-diethyl tartrate yielded the title compound as a colourless oil, 0.63 g (60%) 
which showed identical spectroscopic data to the (S) enantiomer 17a. 
Rac-{2-[6-(Triisopropyl-silyloxy)-hexyl]-oxiranyl}-methanol (17c). To an ice-cold solution of 
8-(triisopropyl-silyloxy)-2-methylene-octan-1-ol 16 (810 mg, 2.58 mmol) in dichloromethane 
(40 mL) was added m-chloroperbenzoic acid (c. 90% pure, 518 mg, 3.0 mmol) portionwise. The 
solution was allowed to warm to room temperature and stirred overnight, then washed with 
aqueous Na2SO3 (2 × 20 mL) aqueous NaHCO3 (2 × 20 mL), and water (20 mL). The solution 
was dried (MgSO4), and concentrated  to yield the title compound as a colourless oil, 820 mg 
(96%), which showed essentially identical spectroscopic data to the (S) enantiomer 17a. Rf 0.43 
(ethyl acetate-petrol, 1 : 4); HRMS: calcd for C15H31O3Si (i.e. M+ – C3H7) 287.2042, found 
287.2047. 
(R)-Mosher’s ester of (S)-{2-[6-(triisopropyl-silyloxy)-hexyl]-oxiranyl}-methanol (18a). To a 
solution of  (S)-{2-[6-(triisopropyl-silyloxy)-hexyl]-oxiranyl}-methanol 17a (200 mg, 0.6 mmol) 
in DMF (5 mL) was added (R)-(+)-α-methoxy-α-trifluoromethylphenylacetic acid (Mosher’s 
acid, 280 mg, 1.20 mmol), DMAP (10 mg, 82 µmol) and powdered 4Å molecular sieves (50 mg), 
and the mixture was cooled to 0 °C under N2. Diisopropyl carbodiimide (171 µL, 139 mg, 1.10 
mmol) was added dropwise, and the whole was allowed to warm to room temperature and stirred 
overnight. The mixture was poured into water and extracted with diethyl ether (2 × 20 mL). The 
combined organic layers were washed with water (2 × 20 mL), saturated aqueous NaHCO3 (20 
mL), 2 M HCl (20 mL) and brine (20 mL), then dried (MgSO4), and concentrated to an oil. 1H 
NMR analysis showed that the crude sample was a 98 : 2 mixture of diastereoisomers. 
Purification by column chromatography on silica (eluting with diethyl ether-petrol, 5 : 95 → 20 : 
80) yielded the product as a colourless oil, 152 mg (50%); Rf 0.67 (diethyl ether-petrol, 1 : 4); 
νmax/cm-1 2942, 2865, 1755, 1171, 1027; δH (300 MHz, CDCl3) 7.47 – 7.45 (m, 2H, 2 × ArH), 
7.37 – 7.32 (m, 3H, 3 × ArH), 4.47 + 4.10 (AB system, J = 11.9 Hz, 2H, CH2OC=O), 3.58 (t, J = 
6.5 Hz, 2H, CH2OSi),  3.49 (s, 3H, CH3O), 2.62 + 2.59 (AB system, J = 4.6 Hz, 2H, epoxide 
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CH2), 1.7 – 1.3 (m, 4H, 2 × CH2), 1.3 - 1.2 (m, 6H, 3 × CH2), 1.00 – 0.98 (m, 21H, 3 × iPr);  δC 
(75.45 MHz, CDCl3) 166.6, 132.4, 130.1, 128.8, 127.7, 126.0, 122.0, 67.8, 63.7, 57.5, 55.9, 50.9, 
33.2, 32.0, 29.8, 26.1, 24.9, 18.4, 12.4; m/z  503 (M+ – C3H7, 24%), 347 (12), 269 (100), 189 
(75); HRMS: calcd for C25H38F3O5Si (i.e. M+ – C3H7) 503.2441, found 503.2438. 
(R)-Mosher’s ester of (R)-{2-[6-(triisopropyl-silyloxy)-hexyl]-oxiranyl}-methanol (18b). (R)-
2-[6-(triisopropyl-silyloxy)-hexyl]-oxiranyl}-methanol 17b was treated with (R)-Mosher’s acid 
as above. 1H NMR analysis before chromatography showed that the crude sample was a 98 : 2 
mixture of diasteroisomers. Column chromatography on silica (eluting with diethyl ether-petrol, 
5 : 95 → 20 : 80) yielded the title compound as a colourless oil, 137 mg (45%); Rf 0.67 (diethyl 
ether-petrol, 1 : 4); νmax/cm-1 2942, 2865, 1755, 1171, 1027; δH (300 MHz, CDCl3) 7.47 - 7.44 
(m, 2H, 2 × ArH), 7.37 – 7.32 (m, 3H, 3 × ArH), 4.42 + 4.20 (AB system, J = 12.0 Hz, 2H, 
CH2O.C=O), 3.59 (t, J = 6.5 Hz, 2H, CH2OSi), 3.48 (s, 3H, CH3O), 2.67 + 2.59 (AB system, J = 
4.7 Hz, 2H, epoxide CH2), 1.7 – 1.3 (m, 4H, 2 × CH2), 1.3 - 1.2 (m, 6H, 3 × CH2), 1.00 – 0.98 
(m, 21H, 3 × iPr); δC (75.45 MHz, CDCl3) 166.6, 132.4, 130.1, 128.9, 127.7, 125.5, 121.7, 67.1, 
63.7, 57.3, 55.8, 50.7, 33.3, 32.3, 29.9, 26.1, 24.8, 18.4, 12.3; m/z  503 (M+ – C3H7, 11%), 347 
(10), 269 (100), 189 (80); HRMS: calcd for C25H38F3O5Si (i.e. M+ – C3H7) 503.2441, found 
503.2438. 
Ethyl (R)-(2-oxiranyl)-(8-triisopropyl-silyloxy)-octanoate (19). To a vigorously stirred 
solution of (S)-{2-[6-(triisopropyl-silyloxy)-hexyl]-oxiranyl}-methanol 17a (3.85 g, 11.7 mmol) 
in tetrachloromethane (25 mL) and acetonitrile (25 mL) at room temperature was added sodium 
periodate (7.44 g, 34.8 mmol) in water (40 mL) followed by ruthenium trichloride trihydrate (50 
mg, 0.19 mmol). After 6 h, the mixture was extracted with dichloromethane (2 × 50 mL), and the 
combined dichloromethane extracts were washed with brine (50 mL), dried (MgSO4) and 
concentrated to a black residue. This was dissolved in anhydrous DMF (20 mL) and treated with 
ethyl iodide (1.7 mL, 3.02 g, 19.2 mmol) followed by portionwise addition of KHCO3 (1.92 g, 
19.2 mmol). The mixture was stirred overnight, then poured into water and extracted with diethyl 
ether (3 × 50 mL). The combined organic layers were dried (MgSO4) and concentrated to a 
residue which was purified by column chromatography on silica (eluting with diethyl ether-
petrol, 5 : 95 → 10 : 90) to yield the product as a colourless oil, 2.08 g (48%); Rf 0.60 (diethyl 
ether-petrol, 1 : 4); νmax/cm-1; δH (300 MHz, CDCl3) 4.23 (m, 2H, CH2CH3), 3.68 (t, J = 6.5 Hz, 
2H, CH2OSi), 3.04 + 2.80 (AB system, J = 5.9 Hz, 2H, epoxide CH2), 2.15 – 2.00 (m, 1H, 0.5 × 
CH2), 1.8 – 1.7 (m, 1H, 0.5 × CH2), 1.7 – 1.5 (m, 4H, 2 × CH2), 1.5 – 1.3 (m, 4H, 2 × CH2), 1.31 
(t, J = 7.1 Hz, 3H, CH3), 1.02 – 1.00 (m, 21H, 3 × iPr); δC (75.45 MHz, CDCl3) 170.8, 63.8, 
61.9, 57.5, 52.2, 33.3, 31.6, 29.8, 26.0, 25.2, 18.4, 14.5, 12.4; m/z  329 (M+ – C3H7, 7 %), 265 
(15), 241 (100), 157 (49); HRMS: calcd for C17H33O4Si (i.e. M+ – C3H7) 329.2148, found 
329.2150. 
Ethyl (R)-(2-oxiranyl)-(8-hydroxy)-octanoate (20). To a solution of ethyl (R)-(2-oxiranyl)-(8-
triisopropyl-silyloxy)-octanoate 19 (2.00 g, 5.4 mmol) in anhydrous THF (60 mL) was added 
TBAF (5.7 mL of a 1.0 M solution in THF, 5.7 mmol) dropwise. The mixture was stirred 1 h, 
then diluted with ethyl acetate (100 mL), washed with saturated aqueous NaHCO3 (50 mL), and 
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filtered through a short pad of silica with further ethyl acetate. The solution was concentrated and 
the residue was purified by column chromatography on silica (eluting with ethyl acetate-petrol, 
40 : 60)  to yield the product as a colourless oil, 890 mg (74%); Rf 0.41 (ethyl acetate-petrol, 1 : 
1); νmax/cm-1 2984, 1742, 1374, 1242, 1048; δH (300 MHz, CDCl3) 4.15 (m, 2H, CH2CH3), 3.57 
(t, J = 6.5 Hz, 2H, CH2OH), 2.96 + 2.71 (AB system, J = 5.9 Hz, 2H, epoxide CH2), 2.1 – 1.9 (m, 
1H, 0.5 × CH2), 1.6 – 1.5 (m, 1H, 0.5 × CH2), 1.50 – 1.25 (m, 8H, 4 × CH2), 1.22 (t, J = 7.1 Hz, 
3H, CH3); δC (75.45 MHz, CDCl3) 170.8, 63.3, 62.0, 57.4, 52.2, 33.0, 31.5, 29.6, 25.9, 25.1, 
14.6; m/z 217 (MH+, 23%), 199 (14), 171 (45), 153 (100), 135 (24); HRMS: calcd for C11H21O4 
(i.e. MH+) 217.1440, found 217.1438. 
Ethyl (R)-2-[6-(2,4-dinitrophenoxy)hexyl]oxiranecarboxylate (4a). (Method A) To a solution 
of ethyl (R)-(2-oxiranyl)-(8-hydroxy)-octanoate 20 (98 mg, 0.45 mmol) in anhydrous DMF (4 
mL) under N2 was added DABCO (250 mg, 2.25 mmol) followed by 1-fluoro-2,4-dinitrobenzene 
(63 µL, 93 mg, 0.49 mmol). The mixture was stirred for 24 h, then poured into water and 
extracted with ethyl acetate (2 × 10 mL). The combined organic extracts were dried (MgSO4) 
and concentrated. Purification by column chromatography on silica (eluting with ethyl acetate-
petrol, 10 : 90 → 50 : 50) yielded the product as a bright yellow oil, 100 mg (58%); Rf 0.59 
(ethyl acetate-petrol, 2 : 3); νmax/cm-1 1609, 1539, 1344, 909, 733 cm-1; δH (300 MHz, CDCl3) 
8.68 (d, J = 2.8 Hz, 1H, ArH),  8.36 (dd, J = 9.3 Hz, 2.8 Hz, 1H, ArH), 7.12 (d, J = 9.3 Hz, 1H, 
ArH), 4.15 (m, 2H, CH2CH3), 4.07 (t, J = 7.2 Hz, 2H, CH2OAr), 2.96 + 2.72 (AB system, J = 5.9 
Hz, 2H, epoxide CH2), 2.1 – 2.0 (m, 1H, 0.5 × CH2), 1.81 (quartet, J = 6.9 Hz, 2H, CH2), 1.6 – 
1.5 (m, 1H, 0.5 × CH2), 1.50 – 1.25 (m, 8H, 4 × CH2), 1.22 (t, J = 7.1 Hz, 3H, CH3); δC (75.45 
MHz, CDCl3) 170.9, 157.4, 140.3, 139.0, 129.4, 122.2, 114.6, 71.1, 62.0, 57.3, 52.3, 31.5, 29.3, 
28.9, 25.9, 25.0, 14.5; m/z  382 (M+, 7%), 369 (16), 345 (21), 295 (42), 107 (53), 55 (100); 
HRMS: calcd for C17H22N2O8 382.1376, found 382.1388. 
Ethyl (R)-2-[6-(2,4-dinitrophenoxy)hexyl]oxiranecarboxylate (4a). (Method B) To a solution 
of 2,4-dinitrophenol (423 mg, 2.30 mmol) and triphenylphosphine (0.60 g, 2.3 mmol) in 
anhydrous THF (5 mL) under N2 at 0 °C was added diethyl azodicarboxylate (362 µL, 400 mg, 
2.30 mmol) dropwise, then, after 10 min, ethyl (R)-(2-oxiranyl)-(8-hydroxy)-octanoate 20 (250 
mg, 1.16 mmol) in THF (2 × 5 mL). The mixture was stirred for 18 h, then poured into dilute 
brine and extracted with ethyl acetate (2 × 50 mL). The organic extracts were combined, washed 
with saturated aqueous NaHCO3, dried (MgSO4) and concentrated. Purification by column 
chromatography on silica (eluting with ethyl acetate-petrol, 25 : 75) yielded the product as a pale 
yellow oil, 270 mg (61%), which showed analytical data identical to material produced by 
method A. 
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